Samer Al Hadidi, MD,MS,FACP
@hadidisamer
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities
ID: 774267564
https://uamshealth.com/provider/samer-a-al-hadidi/ 22-08-2012 18:49:57
5,5K Tweet
4,4K Followers
312 Following
A Clinical Cancer Research article highlights how the FDA-AACR Oncology Educational Fellowship helped four alumni develop their career trajectories. Applications for the next class of fellows are open through Aug 1. Learn more: bit.ly/3SljsIG #AACRSciencePolicy Timil Patel, MD Samer Al Hadidi, MD,MS,FACP
Experts on multiple myeloma provide comprehensive insights on treatment spacing and step-up dosing practices and discuss the long-term utilization of bispecific antibodies. #mmsm | Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Samer Al Hadidi, MD,MS,FACP cancernetwork.com/view/expert-in…
Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for MRD in guiding treatment for relapsed/refractory multiple myeloma. #mmsm | Samer Al Hadidi, MD,MS,FACP cancernetwork.com/view/the-role-…
Manni Mohyuddin x.com/hadidisamer/st…
Study shows most doctors endorsing drugs on X are paid to do so medicalxpress.com/news/2024-05-d… Study by Samer Al Hadidi, MD,MS,FACP Aaron Mitchell et al.
UAMS Health physicians and researchers Tanvi Patel, M.D., UAMS Myeloma Center clinical director Frits van Rhee, M.D., Ph.D., and Samer Al Hadidi, MD,MS,FACP are authors on this paper on ligase modulators and #MultipleMyeloma. sciencedirect.com/science/articl… #uamscancer #WPRCI #uamshealth #mmsm #MedTwitter
Dara-RVd now approved by FDA Oncology for newly diagnosed myeloma patients who are transplant eligible #mmsm ➡️ fda.gov/drugs/resource…
Today's Top Post of the Week is in #mmsm! Coming from our friend Samer Al Hadidi, MD,MS,FACP on updated results of BCMA CAR-T, BCMA BsAb and elranatamab in Multiple Myeloma:
Check our recent paper UAMS Myeloma Center AmericanJournalofHematology #mmsm : Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma ➡️ onlinelibrary.wiley.com/doi/10.1002/aj… ✅n=1379 ✅Median FU:16.6 yrs ✅SHM:5.6% (1 vs 2 transplants=no difference)
Several UAMS Health physicians and researchers, including Samer Al Hadidi, MD,MS,FACP, on this paper in AmericanJournalofHematology regarding primary malignancies after tandem autologous hematopoietic stem cell transplantation. onlinelibrary.wiley.com/doi/10.1002/aj… #uamsmyeloma #uamscancer #uamshealth #mmsm #MedTwitter
Second primary malignancies after tandem autoHCT for multiple myeloma. N=1379 patients, 2640 transplants. Median F/U: ~15 years. 2nd heme malignancy 5.6%, 2nd solid tumor: 7.6%. #mmsm #bmtsm Samer Al Hadidi, MD,MS,FACP onlinelibrary.wiley.com/doi/10.1002/aj…
Experts in multiple myeloma sat down to discuss the use of bispecific antibodies and their impact in the space. #mmsm | Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Samer Al Hadidi, MD,MS,FACP cancernetwork.com/view/bispecifi…
Check our recent pub UAMS Myeloma Center #mmsm Immune prognostic score predicts the risk of infection and survival outcomes in patients with RRMM treated with BsAb ⬆️GPS does not correlate with ORR, PFS, OS, or infection risk. ⬆️CAR HEMATOX ⬆️ all-grade infection rates, ⬇️ORR,PFS,OS
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review The Oncologist #mmsm ➡️academic.oup.com/oncolo/article… Responses to similar treatments are usually lower in smoldering myeloma compared to multiple myeloma👇
Enjoyed discussing Multiple Myeloma: Optimizing the Balance between Efficacy and Quality of Life at the Agrupación Mexicana para el Estudio de la Hematología (AMEH) Virtual Keynote multiple myeloma session #mmsm UAMS Myeloma Center